Total Payments
$112,141
2022 Payments
$21.70
Companies
33
Transactions
196
Medicare Patients
10,191
Medicare Billing
$2.1M
Payment Breakdown by Category
Research$109,078 (97.3%)
Food & Beverage$3,034 (2.7%)
Education$27.95 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $109,078 | 23 | 97.3% |
| Food and Beverage | $3,034 | 171 | 2.7% |
| Education | $27.95 | 2 | 0.0% |
Payments by Type
Research
$109,078
23 transactions
General
$3,062
173 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | $109,078 | 23 | $0 (2018) |
| Novo Nordisk Inc | $277.58 | 19 | $0 (2020) |
| Amgen Inc. | $274.58 | 12 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $245.09 | 7 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $202.05 | 10 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $189.36 | 11 | $0 (2021) |
| Fresenius USA Marketing, Inc. | $169.57 | 12 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $150.33 | 7 | $0 (2019) |
| OPKO Pharmaceuticals, LLC | $148.31 | 13 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $143.77 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $21.70 | 1 | Merck Sharp & Dohme LLC ($21.70) |
| 2021 | $89.14 | 5 | Bayer HealthCare Pharmaceuticals Inc. ($42.91) |
| 2020 | $85.25 | 5 | Amgen Inc. ($27.58) |
| 2019 | $611.22 | 32 | Novo Nordisk Inc ($104.00) |
| 2018 | $110,133 | 89 | Otsuka Pharmaceutical Co., Ltd. ($109,078) |
| 2017 | $1,201 | 64 | AstraZeneca Pharmaceuticals LP ($158.12) |
All Payment Transactions
196 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2022 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Education | In-kind items and services | $21.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Cardio-renal | ||||||
| 10/20/2021 | Avanir Pharmaceuticals, Inc. | Nuedexta (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 09/30/2021 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Cardio-renal | ||||||
| 09/09/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/01/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Cardiovascular | ||||||
| 02/13/2020 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Diabetes | ||||||
| 02/12/2020 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: Nephrology | ||||||
| 02/06/2020 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $12.03 | General |
| 01/22/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/09/2020 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: NEPHROLOGY | ||||||
| 12/18/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Diabetes | ||||||
| 12/12/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Nephrology | ||||||
| 12/05/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Nephrology | ||||||
| 11/14/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: Hypertriglyceridemia | ||||||
| 11/07/2019 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Hyperparathyroidism | ||||||
| 11/01/2019 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Hyperkalemia | ||||||
| 10/17/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Diabetes | ||||||
| 09/25/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Nephrology | ||||||
| 09/19/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/12/2019 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: NEPHROLOGY | ||||||
| 09/06/2019 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2019 | Strongbridge US INC. | KEVEYIS (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Neurology | ||||||
| 08/08/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE NDD-CKD PRO2TECT-CORRECTION | Otsuka Pharmaceutical Co., Ltd. | $62,000 | 11 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE NDD-CKD PRO2TECT-CONVERSION | Otsuka Pharmaceutical Co., Ltd. | $47,078 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 2,665 | 7,671 | $1.8M | $556,407 |
| 2022 | 29 | 2,530 | 7,310 | $1.6M | $503,315 |
| 2021 | 26 | 2,514 | 8,376 | $1.6M | $529,891 |
| 2020 | 24 | 2,482 | 8,532 | $1.5M | $473,056 |
Total Patients
10,191
Total Services
31,889
Medicare Billing
$2.1M
Procedure Codes
107
All Medicare Procedures & Services
107 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 762 | 1,485 | $471,030 | $137,963 | 29.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 100 | 488 | $404,310 | $134,687 | 33.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 77 | 173 | $124,950 | $40,508 | 32.4% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 295 | 571 | $136,702 | $32,753 | 24.0% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 16 | 104 | $69,090 | $23,799 | 34.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 121 | 339 | $81,360 | $21,036 | 25.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 151 | 151 | $23,405 | $19,909 | 85.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 114 | 142 | $68,160 | $19,364 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 145 | 145 | $60,410 | $17,226 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 121 | $44,550 | $16,828 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 255 | $62,365 | $15,992 | 25.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 18 | 2,280 | $45,600 | $13,979 | 30.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 115 | 131 | $56,330 | $12,669 | 22.5% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Office | 2023 | 68 | 78 | $26,520 | $8,263 | 31.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 45 | 132 | $30,120 | $7,354 | 24.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 24 | 27 | $16,200 | $6,099 | 37.6% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 28 | 31 | $19,815 | $5,050 | 25.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 31 | 95 | $7,125 | $4,611 | 64.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 43 | 56 | $17,360 | $3,511 | 20.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 19 | 80 | $4,800 | $3,078 | 64.1% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 59 | 87 | $15,660 | $2,720 | 17.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 53 | 60 | $13,275 | $2,554 | 19.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 25 | 118 | $17,320 | $1,975 | 11.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 174 | $17,400 | $1,926 | 11.1% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 18 | 33 | $4,950 | $984.55 | 19.9% |
About Dr. Piotr Lazowski, MD
Dr. Piotr Lazowski, MD is a Internal Medicine healthcare provider based in Plymouth, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386691012.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Piotr Lazowski, MD has received a total of $112,141 in payments from pharmaceutical and medical device companies, with $21.70 received in 2022. These payments were reported across 196 transactions from 33 companies. The most common payment nature is "" ($109,078).
As a Medicare-enrolled provider, Lazowski has provided services to 10,191 Medicare beneficiaries, totaling 31,889 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 107 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Plymouth, MA
- Active Since 05/28/2006
- Last Updated 06/13/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1386691012
Products in Payments
- Parsabiv (Biological) $206.32
- FARXIGA (Drug) $205.69
- XARELTO (Drug) $202.05
- ENTRESTO (Drug) $189.36
- Tresiba (Drug) $160.65
- ACTHAR (Biological) $143.77
- Velphoro (Drug) $142.24
- Rayaldee (Drug) $137.99
- Uloric (Drug) $127.85
- SAMSCA (Drug) $126.89
- Veltassa (Drug) $123.23
- Auryxia (Drug) $97.47
- Ozempic (Drug) $97.27
- NORTHERA (Drug) $87.11
- JANUVIA (Drug) $79.25
- VIAGRA (Drug) $74.68
- FABRY-DISEASE (Drug) $71.59
- GATTEX (Drug) $63.28
- LYRICA (Drug) $58.72
- INJECTAFER (Drug) $49.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Plymouth
Ms. Beverly Lewis, Md, MD
Internal Medicine — Payments: $171,186
Internal Medicine $171,186
Dr. Jeff The, D.o, D.O
Internal Medicine — Payments: $7,992
Internal Medicine $7,992
Dr. Eugene Valsky, M.d, M.D
Internal Medicine — Payments: $6,811
Internal Medicine $6,811
Lauren Strazzula, M.d, M.D
Internal Medicine — Payments: $5,805
Internal Medicine $5,805
Dr. Anand Singla, Mbbs, MBBS
Internal Medicine — Payments: $5,497
Internal Medicine $5,497
Dr. Christopher Coakley, M.d, M.D
Internal Medicine — Payments: $4,976
Internal Medicine $4,976